Daily pill cuts body weight by up to 13% after 3 months in ... - NBC News
WEBSep 10, 2024 · The rate of weight loss with the experimental pill, called amycretin, appears to be more rapid than what’s seen for other drugs.
Weight loss: Amycretin pill may be more effective than semaglutide
WEBSep 12, 2024 · Early findings from a phase 1 clinical trial first announced by the Danish company Novo Nordisk in March 2024, show that amycretin — an experimental drug they have developed to treat obesity —...
Novo Nordisk experimental obesity pill has mild-to-moderate side ...
WEBSep 10, 2024 · Patients who took 50 mg of amycretin at the end of the 12-week trial reduced body weight by 10.4% on average, while those taking the maximum dose of 2x50 mg lost 13.1% of their starting weight ...
Novo Nordisk’s new weight-loss pill Amycretin beats Wegovy in …
WEBAmycretin’s phase 1 trials show study participants lost 13.1% of their body weight after only 3 months. That’s over twice the amount of weight loss on Wegovy, which shows about 6% weight loss ...
Ozempic Maker Teases New Weight Loss Pill Amycretin - Forbes
WEBMar 7, 2024 · At an investor event on Thursday, Novo Nordisk shared data from an early stage clinical trial of an experimental weight loss drug called amycretin, an oral treatment that trial results suggest...
Novo Nordisk weight loss pill may be more effective than Wegovy …
WEBSep 10, 2024 · In a small Phase 1 trial, a 50-mg dose of the daily pill called amycretin, which activates receptors of both the amylin and GLP-1 hormones, led to 10.4% weight loss at about three months after...
Novo Nordisk’s New Obesity Pill Beats Wegovy In Early Trial
WEBSep 11, 2024 · Data from an early stage clinical trial suggests Novo Nordisk’s new weight loss pill amycretin could produce greater and more rapid weight loss than its popular obesity injection Wegovy.
Novo Nordisk’s oral amycretin tops Wegovy in obesity trial
WEB1 day ago · Novo Nordisk has been boosted by data for an oral obesity therapy, amycretin, that was more effective than injectable Wegovy at reducing weight in a clinical trial.
Novo Nordisk experimental obesity pill has mild-to-moderate side ...
WEBSep 11, 2024 · COPENHAGEN (Reuters) -Novo Nordisk said on Wednesday its highly anticipated experimental weight-loss pill amycretin was safe and tolerable for patients in an early-stage trial, with mild-to ...
Novo’s latest obesity pill spurs major weight loss in small trial
WEBMar 7, 2024 · The drug, called amycretin, is one of a handful of medicines Novo hopes can build on the success of its fast-selling obesity drug Wegovy. Unlike Wegovy, amycretin stimulates two gut hormones, GLP-1 and amylin, that affect appetite and blood sugar levels. It’s also taken orally, not via injections.
Skip to content